Drugmakers Ensnared in Brexit Seek Sway Over Medicine Cabinets
- Separate drug approval processes is ‘doomsday scenario’
- European Medicines Agency may lose local skills, London home
This article is for subscribers only.
The U.K.’s vote to break from the European Union has implications extending all the way to Britons’ medicine cabinets.
At stake is the country’s say in drug approvals for Europe, research funding for its life-sciences industry and patients’ access to critical new medicines. The European Medicines Agency will likely lose its London home and may no longer be able to tap the local scientists and experts who do a third of its work in assessing new treatments.